Trial updateRetina
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Recruiting. Phase 3. Registered enrolment: 304. Amgen
Why it matters
Track this study through NCT07614776. No results are posted in this registry record.
The study at a glance
- Registry status
- Recruiting
- Phase
- Phase 3
- Registered enrolment
- 304
- Results posted
- No
- Sponsor
- Amgen
Keep in mind
Registry information describes the study; recruitment status alone does not establish efficacy or safety.
References (1)
Source date: 17 Sept 2026 · United States · Czechia · Japan · Latvia · Poland · Slovakia